PDCD1 and cancer: While immune checkpoint inhibitors (ICIs) have shown clinical prospects in other cancers, these programmed cell death protein 1 (PD-1) monoclonal antibodies including nivolumab, pembrolizumab, camrelizumab and sintilimab, are approved in advanced HCC based on clinical trials (11–14).